share_log

Wells Fargo Downgrades Integra Lifesciences to Equal-Weight, Lowers Price Target to $25

Wells Fargo Downgrades Integra Lifesciences to Equal-Weight, Lowers Price Target to $25

富國銀行將Integra Lifesciences的評級下調至同等權重,將目標股價下調至25美元
Benzinga ·  05/07 20:43

Wells Fargo analyst Vik Chopra downgrades Integra Lifesciences (NASDAQ:IART) from Overweight to Equal-Weight and lowers the price target from $45 to $25.

富國銀行分析師維克·喬普拉將Integra Lifesciences(納斯達克股票代碼:IART)的評級從增持下調至同等,並將目標股價從45美元下調至25美元。

譯文內容由第三人軟體翻譯。


以上內容僅用作資訊或教育之目的,不構成與富途相關的任何投資建議。富途竭力但無法保證上述全部內容的真實性、準確性和原創性。
    搶先評論